Reply to Office action of April 5, 2008

Appl. No. 10/810,296 Dated April 10, 2008

## REMARKS

XING F WANG

Based on the Office action of April 5, 2008, claims 1, 2 and 9 have been amended and previously presented claims 3-8 and 10 remain in this application.

Each of all dependent claims 2-10 only references or depends from one claim.

Amendments to claims 1, 2 and 9 are based on the Office action and following facts:

- 1. This invention is used to produce a screening report consisting of a total risk, a risk level, a primary cause in the disease, a primary therapy target, a secondary therapy target and a therapy efficiency to the individual who requests the therapy to prevent or treat atherosclerosis-related CHD and stroke, as indicated in the examples 1-5 in pages 7-8 of specification and Figure 2 of the application, which results in all text of the screening report must present in independent claim 1 because the text is the object of this invention.
- 2. The equations 1 and 2 presented in enclosed pages 7-8 of the Office action are unable to yield

Appl. No. 10/810,296 Dated April 10, 2008 Reply to Office action of April 5, 2008

the disease risks  $R_1$  and  $R_2$  because the variables  $Jm_1$ ,  $Jm_2$ ,  $Jn_1$  and  $Jn_2$  of these equations are undetermined, which results in the previously presented equations 1-9 remain in claim 2. Substituting the measured values and normal values of nine atherosclerotic parameters into the remained equations 1-9 in claim 2 yield the nine disease risks  $R_1-R_9$ .

- 3. The labels and unique subscripts to all variables in claims 2 and 9 have been given according to the Office action.
- 4. A repeating of "substituting the measure values  $Cm_1$ ,  $Cm_2$  into equation 1.1 yield  $Jm_1$ ,  $Jm_2$  and substituting the normal values  $Cn_1$ ,  $Cn_2$  into equation 1.1 yield  $Jn_1$ ,  $Jn_2$ " is presented in enclosed pages 8-9 of the Office action. The repeating has been eliminated in claim 2.

These facts indicate it is unnecessary to amend further the claim of the application after the text and form of the claim have been allowed by the two primary examiners of USPTO.

The method of this invention is based on reliability theory background and major clinic and physiology evidences (see the cited references [1]-

Page 31 of 32

Appl. No. 10/810,296 Dated April 10, 2008 Reply to Office action of April 5, 2008

[22] of specification of the application). For example, the method is based on conservation principles of mass, momentum and energy and the equations (1.1)-(1.3) in claim 1 are derived from the conservation principles (see the reference [1]). This invention is strongly supported by the latest review article in atherosclerosis research (Rader et al. Translating molecular discoveries into new therapies for atherosclerosis, Nature, 21 Feb 2008, Vol.451, pp.904-913).

The US patent application has been over 4 years since filed March 27, 2004. The applicant appreciates it if the Notice of Allowance is issued in this case soon.

Respectfully submitted,

Xington Wang

Xing F. Wang, Ph.D.

Applicant

TEL: (774)239-3884 Fax: (508)831-0592

Encl.: the Office action of April 5, 2008 (8 sheets).